First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting.
Overview
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b is a phase 1/2 interventional study registered as NCT03319628 by Mersana Therapeutics, with 523 participants enrolled, started 2017-12-12 and due to reach its primary completion in 2023-05-31. Interventions recorded: upifitamab rilsodotin.
Similar pages
not linked directly; found by shared links- TrialFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.